---
title: "Mentari Therapeutics surges 16%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305182797.md"
description: "Mentari Therapeutics rose 16.07% to US$14.16."
datetime: "2026-11-11T14:50:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305182797.md)
  - [en](https://longbridge.com/en/news/305182797.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305182797.md)
generator: "portal-rs"
---

# Mentari Therapeutics surges 16%

Mentari Therapeutics (MTRI.US) surged more than **16%** during regular trading to **$14.16**.

The Nasdaq Composite is down 1.48% over the past five sessions.

The company completed its merger with InMed Pharmaceuticals on Nov. 6, 2026, and released pro forma combined financial statements. As of June 30, 2026, total cash stood at $478.12 million, total assets at $478.78 million and liabilities at $11.42 million. The net loss was $37.29 million in the first half of 2026, compared with $26.90 million for the full year 2025.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [MTRI.US](https://longbridge.com/en/quote/MTRI.US.md)

## Related News & Research

- [Mentari Therapeutics' Total Liabilities Rise to $78.61 Million From $10.26 Million at Year-End](https://longbridge.com/en/news/305668280.md)
- [Wedbush initiates coverage of Mentari Therapeutics at Outperform, sets price target at $33](https://longbridge.com/en/news/305469432.md)
- [MTRI: PACAP/CGRP pipeline targets more effective, less frequent migraine prevention](https://longbridge.com/en/news/305818527.md)
- [Jefferies initiates coverage of Mentari Therapeutics at Buy, sets price target at $30](https://longbridge.com/en/news/305028486.md)
- [Mentari Therapeutics Publishes Pro Forma Combined Financial Statements With InMed Pharmaceuticals](https://longbridge.com/en/news/305072970.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**